These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8573426)

  • 1. The methodology of clinical trials of oral tiludronate in Paget's disease of bone.
    Roux C
    Bone; 1995 Nov; 17(5 Suppl):497S-499S. PubMed ID: 8573426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.
    Roux C; Gennari C; Farrerons J; Devogelaer JP; Mulder H; Kruse HP; Picot C; Titeux L; Reginster JY; Dougados M
    Arthritis Rheum; 1995 Jun; 38(6):851-8. PubMed ID: 7779130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study.
    Reginster JY; Colson F; Morlock G; Combe B; Ethgen D; Geusens P
    Arthritis Rheum; 1992 Aug; 35(8):967-74. PubMed ID: 1642662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone.
    Reginster JY; Treves R; Renier JC; Amor B; Sany J; Ethgen D; Picot C; Franchimont P
    J Bone Miner Res; 1994 May; 9(5):615-9. PubMed ID: 8053389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paget's disease of bone treated with a five day course of oral tiludronate.
    Reginster JY; Lecart MP; Deroisy R; Ethgen D; Zegels B; Franchimont P
    Ann Rheum Dis; 1993 Jan; 52(1):54-7. PubMed ID: 8427515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone.
    Devogelaer JP; Malghem J; Stasse P; Nagant de Deuxchaisnes C
    Bone; 1997 Mar; 20(3):259-61. PubMed ID: 9071477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
    de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
    Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone.
    Fraser WD; Stamp TC; Creek RA; Sawyer JP; Picot C
    Postgrad Med J; 1997 Aug; 73(862):496-502. PubMed ID: 9307742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and bioequivalence of two oral formulations of tiludronate in the treatment of Paget's disease of bone.
    Morales-Piga A; Del Pino J; Rapado A; Diaz-Curiel M; Pallares M; Gonzalez-Macias J
    Clin Ther; 1997; 19(5):963-74. PubMed ID: 9385484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategy in Paget's disease of bone.
    Meunier PJ; Vignot E
    Bone; 1995 Nov; 17(5 Suppl):489S-491S. PubMed ID: 8573424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tiludronate therapy for Paget's disease of bone.
    McClung MR; Tou CK; Goldstein NH; Picot C
    Bone; 1995 Nov; 17(5 Suppl):493S-496S. PubMed ID: 8573425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of drugs for Paget's disease of bone.
    Reginster JY; Lecart MP
    Bone; 1995 Nov; 17(5 Suppl):485S-488S. PubMed ID: 8573423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
    Chakravarty K; Merry P; Scott DG
    J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tiludronate. A new treatment for an old ailment: Paget's disease of bone.
    Morales-Piga A
    Expert Opin Pharmacother; 1999 Nov; 1(1):157-70. PubMed ID: 11249559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Factors that determine intensity of response to treatment with tiludronate in Paget's disease].
    Morales Piga A; Abraira Santos V; Rey Rey JS; de Abajo Iglesias F
    Med Clin (Barc); 1998 Feb; 110(7):254-8. PubMed ID: 9562949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
    Wimalawansa SJ; Gunasekera RD
    Calcif Tissue Int; 1993 Oct; 53(4):237-41. PubMed ID: 8275351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
    Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.